United BioSource Corporation

United BioSource Corporation

United BioSource Corporation (UBC) was founded in 2003 by industry experts who aimed to generate real-world evidence for specialty therapies with a patient-first approach (per firm website). The firm focuses on evidence generation, drug safety, and patient access — not as an investment manager but as a service provider to biopharma companies. UBC's strategy spans three service lines: evidence development (modernized study designs, real-world evidence strategies), safety and risk management (leadership in Risk Evaluation and Mitigation Strategies, or REMS), and patient access (high-tech and high-touch affordability solutions) (per firm website). The firm serves biopharma clients across multiple therapy areas including oncology, and its solutions target regulators, payers, prescribers, and patients. UBC operates out of headquarters in King of Prussia, Pennsylvania, with additional offices in Florida, Missouri, West Virginia, Switzerland, Spain, and the United Kingdom. In early 2026, UBC appointed Dr. Massoud Toussi as Vice President of Real World Evidence (per firm website, 2026). Toussi brings over 20 years of experience across pharma, CROs, and regulatory work. The firm also participated in the 2026 REMS Industry Consortium Annual Meeting and the ASCO Annual Meeting 2026, signaling ongoing engagement with FDA regulatory trends and oncology-focused stakeholders. UBC is structured as a service organization, not a family office or asset manager. Its core differentiator is the integration of evidence generation, safety compliance, and patient access under one roof — a model purpose-built for the complex regulatory and commercial pathway of specialty therapies. This tripartite offering allows UBC to serve as a single partner across the product lifecycle, from late-stage research to post-market surveillance.